The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Key advancements in lymphoma research and treatment from ASH 2024
Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, shares her highlights from ASH 2024, including a US intergroup study that showed no benefit in adding autologous stem cell transplant to maintenance rituximab for patients with measurable residual disease (MRD)-negative and positron emission tomography (PET)-negative mantle cell lymphoma. Dr LaCasce notes the innovations that have been made in lymphoma treatment in recent years and expresses optimism regarding patient outcomes. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
It was an interesting meeting. I think probably the most interesting data was in mantle cell lymphoma. So, you know, there was the U.S. intergroup study led by ECOG that showed for patients who were MRD negative and PET negative at the end of induction therapy, there was no benefit to adding an autologous stem cell transplant to maintenance rituximab, which supports the prior TRIANGLE study, though that asks a different question...
It was an interesting meeting. I think probably the most interesting data was in mantle cell lymphoma. So, you know, there was the U.S. intergroup study led by ECOG that showed for patients who were MRD negative and PET negative at the end of induction therapy, there was no benefit to adding an autologous stem cell transplant to maintenance rituximab, which supports the prior TRIANGLE study, though that asks a different question. But I think that’s really a big step forward in mantle cell lymphoma. As we know, stem cell transplantation can be associated with significant toxicity. So that was pretty exciting. And a lot of more data with bispecific antibodies and combinations. And I think the overall message in lymphoma is, there’s been a lot of innovation in the past five to 10 years, and we’re really seeing amazing improvements and outcomes across the board for B-cell lymphomas. We still have a ways to go for T-cell lymphoma and Hodgkin lymphoma we’ve already talked about, but our patients generally do really well. So it’s a pretty great time to be a lymphoma doc, I would say.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Genmab: Consultancy, Honoraria; Research to Practice: Speakers Bureau; Pierre Fabre: Consultancy.
